OS Therapies Inc. has released a corporate presentation detailing their advancements and investment highlights. Over $300 million has been invested in their listeria platform, with a focus on the OST-HER2 program targeting osteosarcoma and other solid tumor cancers. The total addressable market for these assets and applications is estimated at $258 billion. The presentation also outlines their OST-tADC platform, featuring a unique patented silicone linker aimed at improving safety and efficacy. The company's clinical-stage pipeline includes programs in osteosarcoma, HPV cancers, non-small cell lung cancer, glioblastoma, breast cancer, and prostate cancer, with positive Phase 2b data in some areas. OS Therapies is targeting accelerated approval for certain programs in late 2025. You can access the full presentation through the link below.